… Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell
lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds …

… This study had successfully done the comparative studies for Otsu’s thresholding, watershed
segmentation and k-mean clustering for image segmentation of lung cancer detection. The …

… the number of patients with lung cancer presenting as solitary thin-walled cavity studied here
is the largest in the English language literature. The thin-walled cavity lung cancer might be …

… are approved for treatment of this cancer, largely … comparative analyses of lung SCC,
we probed somatic genome alterations of lung SCC by using samples from Korean patients…

… cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell
lung carcinoma and accounts for approximately 85% of all lung cancers (1). NSCLCs are …

Full article: Clinical comparative investigation of efficacy and toxicity of cisplatin plus gemcitabine
or plus Abraxane as first-line chemotherapy for stage III/IV non-small-cell lung cancer …

… A major goal of our research is to verify the hypothesis that inhibiting expression of certain
key convertases may disrupt the autocrine loop that promotes lung cancer cell proliferation. …

… Lung cancer is the leading cause of cancer-related deaths in many countries. Approximately
one third of patients with non–small-cell lung cancer (NSCLC) have metastatic disease at …

… The purpose of the present study was to present the treatment outcomes of particle … small
cell lung cancer, including a comparative analysis involving pathologically proven lung cancer (…

… The vast majority, more than 95%, of these patients develop small-cell lung cancer because
of tobacco smoking. The risk of developing the cancer increases both with the number of …